Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Xylometazoline HCl (xylomethazoline; Otrivine; Amidrin; Balkis; Chlorohist-LA; Decongest; espa-rhin; Gelonasal), the hydrochloride salt of Xylometazoline, is an α-adrenoceptor agonist commonly used as nasal decongestant.shows maximum potency at the α2B-adrenoceptor subtype with EC50 of 99 μM. Xylometazoline, a α-adrenoceptor agonist that is frequently used as a nasal decongestant, has an EC50 of 99 μM and is most potent at the α2B-adrenoceptor subtype. With an IC50 of 0.08, 0.56, 0.45, 0.98, 1.8, and 0.22 μM, respectively, xylometazoline binds at adrenoceptor subtypes α1A, α1B, α1D, α2A, α2B, and α2C.
Targets |
Alpha-1A adrenergic receptor ( Ki = 0.05 μM ); Alpha-1B adrenergic receptor ( Ki = 0.30 μM ); Alpha-1D adrenergic receptor ( Ki = 0.15 μM ); Alpha-2A adrenergic receptor ( Ki = 0.88 μM ); Alpha-2B adrenergic receptor ( Ki = 1.7 μM ); Alpha-2C adrenergic receptor ( Ki = 0.19 μM nM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C16H25CLN2
|
---|---|
Molecular Weight |
280.84
|
Exact Mass |
280.17
|
Elemental Analysis |
C, 68.43; H, 8.97; Cl, 12.62; N, 9.98
|
CAS # |
1218-35-5
|
Appearance |
White to off-white crystalline powder
|
SMILES |
CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl
|
InChi Key |
YGWFCQYETHJKNX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C16H24N2.ClH/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15;/h8-9H,6-7,10H2,1-5H3,(H,17,18);1H
|
Chemical Name |
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride
|
Synonyms |
xylomethazoline; Xylometazoline HCl; Brand name: Decongest; Otrivine; Balkis; Amidrin; Chlorohist-LA; espa-rhin; Gelonasal
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5607 mL | 17.8037 mL | 35.6075 mL | |
5 mM | 0.7121 mL | 3.5607 mL | 7.1215 mL | |
10 mM | 0.3561 mL | 1.7804 mL | 3.5607 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05334017 | Completed | Drug: Xylometazoline 0,1% Drug: Cocaine 4% |
Epistaxis | Rigshospitalet, Denmark | September 8, 2022 | Phase 4 |
NCT03424889 | Completed | Drug: Xylometazoline Drug: Saline |
Bronchoscopy | All India Institute of Medical Sciences, New Delhi |
June 1, 2018 | Not Applicable |
NCT00452270 | Completed | Drug: Xylometazoline | Common Cold | Novartis | March 2007 | Phase 3 |
NCT00622817 | Completed | Drug: xylometazoline HCL 0.05% Drug: Epinephrine 1mg |
Bronchiolitis | Schneider Children's Medical Center, Israel |
October 2004 | Not Applicable |